ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

デフェロキサミン

Deferoxamine

HCID 2973
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
70-51-9
標準SMILES
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
InChIKey
UBQYURCVBFRUQT-UHFFFAOYSA-N
分子式
C25H48N6O8
平均分子量
560.7 g/mol
単同位体質量
560.3533625

概要

Desferrioxamine B is an acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N1-(5-aminopentyl)-N1-hydroxy-N4-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator. It has a role as a ferroptosis inhibitor, a siderophore, an iron chelator and a bacterial metabolite. It is a conjugate base of a desferrioxamine B(1+). It is a conjugate acid of a desferrioxamine B(3-).

名称と識別子

優先名称
Deferoxamine
IUPAC
N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide
現地名
デフェロキサミン
英語名
Deferoxamine
分子式
C25H48N6O8
分子量
560.69

名称と別名

deferoxamine70-51-9Desferrioxamine BDESFERRIOXAMINEDeferrioxamineDeferoxamine BDeferrioxamine BDeferoxaminDeferoxaminumDesferinDFOMDesferan
名称をさらに表示
デフェロキサミンN-ヒドロキシ-N-[1,4-ジオキソ-4-[5-(アセチルヒドロキシアミノ)ペンチルアミノ]ブチル]-N′-[1,4-ジオキソ-4-(5-アミノペンチルヒドロキシアミノ)ブチル]-1,5-ペンタンジアミンN-(5-アミノペンチル)-N-ヒドロキシ-3-[5-[3-[5-(アセチルヒドロキシアミノ)ペンチルカルバモイル]プロパノイルヒドロキシアミノ]ペンチルカルバモイル]プロパンアミドN-(5-アミノペンチル)-N-ヒドロキシ-N'-[5-(N-ヒドロキシ-3-{[5-(N-ヒドロキシアセトアミド)ペンチル]カルバモイル}プロパンアミド)ペンチル]ブタンジアミドN′-[5-[[4-[[5-(アセチルヒドロキシアミノ)ペンチル]アミノ]-1,4-ジオキソブチル]ヒドロキシアミノ]ペンチル]-N-(5-アミノペンチル)-N-ヒドロキシブタンジアミドデフェリオキサミンN-(5-アミノペンチル)-4-[5-[ヒドロキシ[3-[5-(アセチルヒドロキシアミノ)ペンチルカルバモイル]プロピオニル]アミノ]ペンチルアミノ]-4-オキソブタンヒドロキサム酸N-[5-[アセチル(ヒドロキシ)アミノ]ペンチル]-N′-ヒドロキシ-N′-[5-[4-[5-アミノペンチル(ヒドロキシ)アミノ]-1,4-ジオキソブチルアミノ]ペンチル]ブタンジアミドデスフェリオキサミンBデフェロキサミドBN-[5-[[4-[(5-アミノペンチル)(ヒドロキシ)アミノ]-4-オキソブチリル]アミノ]ペンチル]-N-ヒドロキシ-N′-[5-[(アセチル)(ヒドロキシ)アミノ]ペンチル]ブタンジアミドN′′′-[5-[ヒドロキシ(アセチル)アミノ]ペンチル]-N-(5-アミノペンチル)[N′,N′′-(ペンタメチレン)ビス(N-ヒドロキシスクシンアミド)]

物性

構造計算による物性補完中

XLogP
-2.1
極性表面積
206 Ų
水素結合供与体数
6
水素結合受容体数
9
回転可能結合数
23
重原子数
39
形式電荷
0
複雑度
739

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LipidsFatty Acyls [FA] -> Fatty amides [FA08] -> N-acyl amines [FA0802]
LogP · 2 件

-2.2

-1.52

Solubility9.90e-02 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Chelating Agents; Iron Chelating Agents

Antidotes and other substances used in poisonings > Specific

Melting Point · 3 件

MP: 138-140 °C /MONOHYDRATE/; 172-175 °C /HYDROCHLORIDE/; 148-149 °C /METHANESULFONATE/

MP: 180-182 °C /N-ACETYL DERIV/

138 - 140 °C

Physical DescriptionSolid
Stability/Shelf LifeRECONSTITUTED SOLN ARE STABLE FOR 2 WK @ ROOM TEMP /MESYLATE/
Collision Cross Section228.86 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (97.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 69 reports by companies from 3 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory InformationStatus: Active Update: 07-06-2016 https://echa.europa.eu/registration-dossier/-/registered-dossier/17782
Hazard Classes and CategoriesAcute Tox. 4 (97.1%)

毒性情報

InteractionsTHE CONCOMITANT ORAL ADMINISTRATION OF ASCORBIC ACID (0.5 TO 1 G TWICE DAILY) SEEMS TO IMPROVE THE CHELATING ACTION OF DEFEROXAMINE IN HEMOCHROMATOSIS, PARTICULARLY IF THERE IS A VITAMIN C DEFICIENCY.
Hepatotoxicity · 1 件

In large clinical trials, elevations in serum aminotransferase levels were rare in patients receiving deferoxamine and instances of acute, clinically apparent liver injury were not reported. Patients with transfusion related iron overload often have concurrent chronic hepatitis B or C, and elevations of serum aminotransferase levels during chelation therapy may be due to natural fluctuations in the underlying chronic liver disease activity. Nevertheless, elevations in serum aminotransferase levels and “hepatic dysfunction” are listed as potential adverse events in product labels for deferoxamine. After an early report of hepatitis occurring in patient on hemodialysis receiving deferoxamine to reduce aluminum levels, there have been no further published instances of clinically apparent liver injury that have been convincingly linked to deferoxamine therapy.

Adverse Effects

化学と産業

薬理情報

ATC Code · 4 件

V03AC01

V - Various

QV - Various

V03AC01

Protein BindingLess than 10% bound to serum proteins <i>in vitro</i>.
Pharmacodynamics · 1 件

Deferoxamine, otherwise known as desferrioxamine or desferal, is a chelating agent used to remove excess iron or aluminum from the body. It acts by binding free iron or aluminum in the bloodstream and enhancing its elimination in the urine. By removing excess iron or aluminum, the agent reduces the damage done to various organs and tissues, such as the liver.

Mechanism of Action · 3 件

Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex. The formation of aluminoxamine increases blood concentrations of aluminum, resulting in an increased concentration gradient between the blood and dialysate, boosting the removal of aluminum during dialysis. 100 mg of deferoxamine is capable of binding approximately 4.1 mg of aluminum.

DEFEROXAMINE HAS...REMARKABLY HIGH AFFINITY FOR FERRIC IRON... IT...COMPETES FOR IRON OF FERRITIN & HEMOSIDERIN, BUT IT REMOVES ONLY SMALL AMOUNT OF IRON OF TRANSFERRIN. ... GIVEN ORALLY, DEFEROXAMINE BINDS IRON IN LUMEN OF BOWEL & RENDERS THE METAL NONABSORBABLE.

IT READILY COMPLEXES WITH FERRIC ION TO FORM FERRIOXAMINE, COLORED, STABLE, WATER-SOL CHELATE; IT ALSO HAS LIMITED AFFINITY FOR FERROUS ION. /MESYLATE/

Biological Half-LifeBiphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.
Metabolism/Metabolites · 2 件

Deferoxamine is mainly metabolised in the plasma and hepatic metabolism is minimal. A number of metabolites have been isolated but not characterised. Some metabolites of deferoxamine, most notably the product of oxidative deamination, also chelate iron, and thus the antidotal effect of the drug appears unaffected by hepatic metabolism.

関連反応

16 件
反応記録を作成
HRID 24973 の反応式
HRID 24973反応物として
HRID 24974 の反応式
HRID 24974反応物として
HRID 24975 の反応式
HRID 24975反応物として
HRID 979002 の反応式
HRID 979002反応物として
HRID 1061480 の反応式
HRID 1061480反応物として
HRID 1376572 の反応式
HRID 1376572生成物として反応物として
HRID 1376573 の反応式
HRID 1376573生成物として反応物として
HRID 1376574 の反応式
HRID 1376574生成物として反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
デフェリフェリオキサミンB
デスフェリオキサミン
N′-[5-[[4-[[5-(アセチルヒドロキシアミノ)ペンチル]アミノ]-1,4-ジオキソブチル]ヒドロキシアミノ]ペンチル]-N-(5-アミノペンチル)-N-ヒドロキシスクシンアミド
デスフェロキサミン
デフェリオキサミンB
デスフェリ-フェリオキサミンB
N-[5-[4-[ヒドロキシ(5-アミノペンチル)アミノ]-1,4-ジオキソブチルアミノ]ペンチル]-N-ヒドロキシ-N′-[5-(アセチルヒドロキシアミノ)ペンチル]ブタンジアミド
フェリオキサミンB
DESFEROXAMINE
taone
entaone
ba33112
ba-29837
ba-33112
DesferexDesferralDesferrinN-Benzoylferrioxamine BDeferoxaminaDFOANSC-527604Ferrioxamine B, N-benzoyl-

データベース識別子

CAS
70-51-9
PubChem CID
2973
DTXSID
DTXSID7022887
ChEMBL
CHEMBL556
ChEBI
CHEBI:4356
UNII
J06Y7MXW4D
EC Number
200-738-5
Nikkaji
J10.199K
Other Experimental Properties · 4 件

CRYSTALS FROM DIL ALC /MONOHYDRATE/

CRYSTALS FROM SLIGHTLY ACIDIC METHANOL /HYDROCHLORIDE/

CRYSTALS FROM DIL ALC /METHANESULFONATE/

CRYSTALS FROM N-PROPANOL /N-ACETYL DERIV/

物理化学的性質

融点
139 °C · 139°C
沸点
627.9 °C · 627.9°C (rough estimate)
比重(密度)
1.2216 · 1.2216 (rough estimate)
屈折率
1.554 · 1.5540 (estimate)
貯蔵温度
-20 °C · -20°C
外見
Solid
酸解離定数(Pka)
9.08 · 9.08±0.50(Predicted)
色
White to off-white
主な用途
医薬品
InChIKey
UBQYURCVBFRUQT-UHFFFAOYSA-N
SMILES
C(=O)(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C
EPAの化学物質情報
Deferoxamine (70-51-9)
· 1 件

Chronic deferoxamine therapy can lead to sensorineural hearing loss and retinopathy. Though the mechanism of ocular injury is not well understood, it appears to partially occur due to damage to the retinal pigment epithelium, which can lead to decreased visual acuity, visual field defects, and color vision defects. Hearing and vision loss can be reversible if the patient discontinues the drug early in the course. Growth retardation can also occur in children receiving deferoxamine treatment, and clinicians should monitor patients for appropriate growth velocity over time.

Toxicity SummaryPatients tolerate deferoxamine well, and there is no specific antidote for the medication. The precautions and dose reductions are described elsewhere in this paper.
Human Toxicity Excerpts · 4 件

PAIN & INDURATION MAY OCCUR @ SITE OF IM INJECTION. OTHER UNTOWARD EFFECTS INCL ERYTHEMA, FLUSHING, DIARRHEA, BLURRING OF VISION, ABDOMINAL DISCOMFORT, MUSCULAR SPASMS IN LEGS, ITCHING, TACHYCARDIA, & FEVER. IN LONG TERM THERAPY, VARIOUS ALLERGIC REACTIONS, INCL ANAPHYLAXIS, HAVE BEEN REPORTED. /MESYLATE/

REACTIONS HAVE INCLUDED HYPOTENSION, PROBABLY DUE TO HISTAMINE RELEASE (ESP DURING IV ADMIN), SKIN RASHES, & GI IRRITATION. OCCASIONAL CASES OF CATARACT FORMATION IN MAN HAVE BEEN REPORTED...

A WOMAN WITH BETA-THALASSAEMIA INTERMEDIA, AND IRON OVERLOAD FOLLOWING MANY YEAR'S THE COURSE OF THIS TREATMENT SHE DEVELOPED TINNITUS, WHICH WAS CONSIDERED TO BE A RARE COMPLICATION OF THE USE OF THIS CHELATING AGENT.

DESFERRIOXAMINE WAS GIVEN INTRAVENOUSLY, AT HIGHER DOSES THAN PREVIOUSLY REPORTED, TO COUNTER THE EFFECTS OF TRANSFUSION-INDUCED IRON OVERLOAD IN FOUR PATIENTS WITH BETA THALASSAEMIA MAJOR. IN TWO OF THEM RETINAL ABNORMALITIES DEVELOPED, PRESENTING WITH NIGHT BLINDNESS AND FIELD DEFECTS, WHICH IMPROVED ON WITHDRAWAL OF THE DRUG.

Drug Induced Liver Injury · 6 件

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

deferoxamine

Desferal®

Chelating agents

Not Applicable

no-DILI-concern

Non-Human Toxicity Excerpts · 5 件

DOGS TOLERATE SINGLE IV DOSES UP TO 100 MG/KG WITH SIGNS SUGGESTING TRANSIENT HYPOTENSION.

...IT HAS PRODUCED OPACITIES IN CRYSTALLINE LENS IN DOGS, CATS, & RATS WHEN GIVEN BY DAILY SC INJECTION FOR LONG PERIODS @ DOSAGES SO LARGE THAT THEY PRODUCE SEVERE GASTROENTERITIS.

INJECTION OF 28.5% SOLN SUBCONJUNCTIVALLY HAS CAUSED SLIGHT CHEMOSIS & HYPEREMIA. ... INJECTION OF 50 MG SUBCONJUNCTIVALLY WAS TOLERATED BY EYES OF MONKEYS...

...50 MG INJECTED SUBCONJUNCTIVALLY IN RABBITS EVERY 1-3 DAYS FOR SEVERAL MO WAS TOLERATED...BUT 200 MG SUBCONJUNCTIVALLY IN RABBITS CAUSED REDN IN RESPONSE OF PUPIL TO LIGHT, CONGESTION OF UVEA, & EXUDATIVE DETACHMENT OF CHOROID & RETINA...

INTRAVITREAL INJECTIONS OF 5 MG DEFEROXAMINE IN RABBITS PROVED VERY TOXIC, CAUSING WIDESPREAD HEMORRHAGIC NECROSIS, PARTICULARLY AFFECTING RODS & CONES OF RETINA & EXTINGUISHING ELECTRORETINOGRAM.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
WGK 3
毒性
LD50 oral in mouse: 1340mg/kg
ストレージクラス
11 - Combustible Solids
有毒物質データの
70-51-9(Hazardous Substances Data)

DEFEROXAMINE IS METABOLIZED PRINCIPALLY BY PLASMA ENZYMES, ALTHOUGH THE PATHWAYS HAVE NOT YET BEEN DEFINED.

FDA Pharmacological Classification · 5 件

J06Y7MXW4D

DEFEROXAMINE

Mechanisms of Action [MoA] - Iron Chelating Activity

Established Pharmacologic Class [EPC] - Iron Chelator

Deferoxamine is an Iron Chelator. The mechanism of action of deferoxamine is as an Iron Chelating Activity.

MeSH Pharmacological ClassificationLow-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994)
Absorption, Distribution and Excretion · 3 件

Deferoxamine is rapidly absorbed after intramuscular or subcutaneous administration, but only poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.

Deferoxamine mesylate is metabolized principally by plasma enzymes, but the pathways have not yet been defined. Some is also excreted in the feces via the bile.

THE DRUG IS...READILY EXCRETED IN URINE.

Cellular LocationsCytoplasm

用途と製造

Uses · 2 件

MEDICATION

Use (kg; approx.) in Germany (2009): >100

Methods of ManufacturingNATURAL PRODUCT FORMING IRON COMPLEXES, ISOLATED FROM STREPTOMYCES PILOSUS, ETTLINGER ET AL, ISOLATION: BICKEL ET AL, HELV CHIM ACTA 43, 2118 (1960). PREPN FROM FERRIOXAMINE B & STRUCTURE: BICKEL ET AL, HELV CHIM ACTA 43, 2129 (1960).
Formulations/Preparations · 2 件

STERILE DEFEROXAMINE MESYLATE, USP (DESFERAL MESYLATE), IS AVAILABLE IN AMPULES CONTAINING 500 MG OF THE DRUG. /MESYLATE/

DESFERAL (CIBA). INJECTION: LYOPHILIZED POWDER (FOR SOLN) 500 MG.

General Manufacturing Information · 1 件

THE IRON-CHELATING AGENT DESFERROXAMINE INHIBITED BOTH THE BASELINE AND IRON-STIMULATED AUTOXIDATION OF DOPAMINE OR NOREPINEPHRINE. DESFERROXAMINE APPEARS TO BE A USEFUL TOOL THAT MAY BE ADDED TO SOLUTIONS CONTAINING CATECHOLAMINES TO PREVENT THEIR DEGRADATION.

応用分野 · 2 件

説明Deferoxamine was introduced in the 1960s for chelation of iron. It is synthesized by removing a central iron molecule from ferrioxamine B, a compound obtained from the microorganism Streptomyces pilosus. Deferoxamine binds to iron from ferritin and forms ferrioxamine, a very stable and water-soluble chelate with a characteristic reddish color.

使用Deferoxamine is used for the treatment of both acute iron intoxication and chronic iron overload due to transfusiondependent anemias. It has also been used in trials for malaria treatment and for aluminum chelation in hemodialysis patients. Studies of a rat model of intracerebral hemorrhage have noted that deferoxamine treatment reduced oxidative stress from iron release, indicating a possible role in preventing damage associated with hemorrhagic strokes.

上流・下流製品情報

上流原料

N,N'-ジシクロヘキシルカルボジイミドシアノ水素化ほう素ナトリウムO-ベンジルヒドロキシルアミン 塩酸塩こはく酸無水物水酸化パラジウム / 炭素無水酢酸アルミニウムニッケル触媒N6,N6-ジメチルアデニン4-[(5-{[(benzyloxy)carbonyl]amino}pentyl)(hydroxy)amino]-4-oxobutanoic acidButanoic acid, 4-[(4-cyanobutyl)(phenylmethoxy)amino]-4-oxo-benzyl N-[5-(N-hydroxy-3-{[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]carbamoyl}propanamido)pentyl]carbamateButanediamide, N'-[5-[[4-[[5-[acetyl(phenylmethoxy)amino]pentyl]amino]-1,4-dioxobutyl](phenylmethoxy)amino]pentyl]-N-(4-cyanobutyl)-N-(phenylmethoxy)- (9CI)(5-Aminopentyl)(phenylmethoxy)carbamic acid tert-butyl esterbenzyl 5-(3,6-dioxomorpholino)pentylcarbamateBenzyl (5-(hydroxyaMino)pentyl)carbaMate